Knowledge, experiences, and perceptions of medications for opioid use disorder among Black Kentuckians

References

• SAMHSA. The opioid crisis and the Black/African American population: an urgent issue. 2020. Available from: https://store.samhsa.gov/sites/default/files/pep20-05-02-001.pdf
   Google Scholar
• Slavova S, Freeman PR, Rock P, et al. 2022. Changing trends in drug overdose mortality in Kentucky: an examination of race and ethnicity, age, and contributing drugs, 2016-2020. Public Health Rep, 00333549221074390.
   Google Scholar
• Parlier-Ahmad AB, Pugh M, Martin CE. Treatment outcomes among black adults receiving medication for opioid use disorder. J Racial Ethnic Health Disparities. 2022;9(4):1–10. doi:10.1007/s40615-021-01095-4.
   PubMed Web of Science ®Google Scholar
• James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018;46(2):404–421. doi:10.1177/1073110518782949.
   PubMed Web of Science ®Google Scholar
• Santoro TN, Santoro JD. Racial bias in the US opioid epidemic: a review of the history of systemic bias and implications for care. Cureus. 2018;10(12):e3733.
   PubMedGoogle Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, et al. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for african americans. Drug Alcohol Depend. 2013;128(3):222–229. doi:10.1016/j.drugalcdep.2012.08.027.
   PubMed Web of Science ®Google Scholar
• Stahler GJ, Mennis J, Baron DA. Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US. Drug Alcohol Depend. 2021;226:108849. doi:10.1016/j.drugalcdep.2021.108849.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35. doi:10.1080/10550887.2016.1100960.
   PubMed Web of Science ®Google Scholar
• Barnett ML, Meara E, Lewinson T, et al. Racial inequality in receipt of medications for opioid use disorder. N Engl J Med. 2023;388(19):1779–1789. doi:10.1056/NEJMsa2212412.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Wharam JF, Schuster MA, et al. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017;171(8):747–755. doi:10.1001/jamapediatrics.2017.0745.
   PubMed Web of Science ®Google Scholar
• Hollander MAG, Chang CH, Douaihy AB, et al. Racial inequity in medication treatment for opioid use disorder: exploring potential facilitators and barriers to use. Drug Alcohol Depend. 2021;227:108927. doi:10.1016/j.drugalcdep.2021.108927.
   PubMed Web of Science ®Google Scholar
• Alexander M. 2012. The new Jim Crow: mass incarceration in the age of colorblindness. Revised ed. New York (NY): New Press.
   Google Scholar
• Yearby R, Clark B, Figueroa JF. Structural racism in historical and modern US health care policy. Health Aff (Millwood). 2022;41(2):187–194. doi:10.1377/hlthaff.2021.01466.
   PubMed Web of Science ®Google Scholar
• Nieweglowski K, Corrigan PW, Tyas T, et al. Exploring the public stigma of substance use disorder through community-based participatory research. Addict Res Theory. 2018;26(4):323–329. doi:10.1080/16066359.2017.1409890.
   Web of Science ®Google Scholar
• Dickson-Gomez J, Spector A, Weeks M, et al. “You’re not supposed to be on it forever”: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abus. 2022;16:11782218221103859.
   Web of Science ®Google Scholar
• Velasquez M, Flannery M, Badolato R, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37. doi:10.1186/s13722-019-0166-0.
   PubMed Web of Science ®Google Scholar
• Beachler T, Zeller TA, Heo M, et al. Community attitudes toward opioid use disorder and medication for opioid use disorder in a rural Appalachian county. J Rural Health. 2021;37(1):29–34. doi:10.1111/jrh.12503.
   PubMed Web of Science ®Google Scholar
• Adams ZW, Taylor BG, Flanagan E, et al. Opioid use disorder stigma, discrimination, and policy attitudes in a national sample of U.S. young adults. J Adolesc Health. 2021;69(2):321–328. doi:10.1016/j.jadohealth.2020.12.142.
   PubMed Web of Science ®Google Scholar
• Kariisa M, Davis NL, Kumar S, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics – 25 states and the District Of Columbia, 2019–2020. MMWR Morb Mortal Wkly Rep. 2022;71(29):940–947. doi:10.15585/mmwr.mm7129e2.
   PubMed Web of Science ®Google Scholar
• Hoopsick RA, Homish GG, Leonard KE. Differences in opioid overdose mortality rates among middle-aged adults by race/ethnicity and sex, 1999-2018. Public Health Rep. 2021;136(2):192–200. doi:10.1177/0033354920968806.
   PubMed Web of Science ®Google Scholar
• Golub A, Johnson BD, Dunlap E. Subcultural evolution and illicit drug use. Addict Res Theory. 2005;13(3):217–229. doi:10.1080/16066350500053497.
   PubMed Web of Science ®Google Scholar
• Cockrell JR, Folstein MF. Mini-mental state examination. In: Abou-Saleh MT, Katona CLE, Anand KA, editors. Principles and practice of geriatric psychiatry. 2002 ed. Chichester (UK): John Wiley & Sons, Ltd.; 2002. p. 140–141. doi:10.1002/0470846410.ch27(ii).
   Google Scholar
• Hargons C, Miller-Roenigk B, Malone N, et al. “Can we get a Black rehabilitation center?”: factors impacting the treatment experiences of Black people who use opioids. J Subst Abuse Treat. 2022;142:108805. doi:10.1016/j.jsat.2022.108805.
   PubMed Web of Science ®Google Scholar
• Emergent Devices, Inc. Introduction. 2021. Available from: https://www.narcan.com/hcp/narcan-introduction
   Google Scholar
• Sociocultural Research Consultants, LLC. Dedoose [computer software]. 2021.
   Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi:10.1191/1478088706qp063oa.
   Google Scholar
• Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: what role does stigma play? Subst Abus. 2019;40(4):459–465. doi:10.1080/08897077.2019.1640833.
   PubMed Web of Science ®Google Scholar
• Hansen H, Siegel C, Wanderling J, et al. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21. doi:10.1016/j.drugalcdep.2016.03.028.
   PubMed Web of Science ®Google Scholar
• Staton M, Pike E, Tillson M, et al. Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia. J Community Psychol. 2023. doi:10.1002/jcop.23029.
   PubMed Web of Science ®Google Scholar
• Rigg KK, Weaver R, Kusiak E. Attitudes toward methadone treatment among Black/African Americans: implications for engagement and retention. Am J Orthopsychiatry. 2023;93(6):476–485. doi:10.1037/ort0000692.
   PubMedGoogle Scholar
• Sharp A, Carlson M, Howell V, et al. Letting the sun shine on patient voices: perspectives about medications for opioid use disorder in Florida. J Subst Use Addict Treat. 2021;123:108247. doi:10.1016/j.jsat.2020.108247.
   Google Scholar
• Krans EE, Kim JY, James AE, 3rd, et al. Medication-assisted treatment use among pregnant women with opioid use disorder. Obstet Gynecol. 2019;133(5):943–951. doi:10.1097/AOG.0000000000003231.
   PubMed Web of Science ®Google Scholar
• Schiff DM, Nielsen T, Hoeppner BB, et al. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. JAMA Netw Open. 2020;3(5):e205734. doi:10.1001/jamanetworkopen.2020.5734.
   PubMed Web of Science ®Google Scholar
• Chenworth M, Perrone J, Love JS, et al. Methadone and suboxone® mentions on twitter: thematic and sentiment analysis. Clin Toxicol (Phila). 2021;59(11):982–991. doi:10.1080/15563650.2021.1893742.
   PubMed Web of Science ®Google Scholar
• McKenzie M, Nunn A, Zaller ND, et al. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manage. 2009;5(4):219–227. doi:10.5055/jom.2009.0024.
   PubMedGoogle Scholar
• Brown AR. Health professionals’ attitudes toward medications for opioid use disorder. Subst Abus. 2022;43(1):598–614. doi:10.1080/08897077.2021.1975872.
   PubMed Web of Science ®Google Scholar
• Madden EF, Prevedel S, Light T, et al. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181–2201. doi:10.1080/10826084.2021.1975749.
   PubMed Web of Science ®Google Scholar
• Pro G, Zaller N. Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings. PLoS One. 2020;15(2):e0228755. doi:10.1371/journal.pone.0228755.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17(5):396–401. doi:10.1080/10550490802268835.
   PubMed Web of Science ®Google Scholar
• Grella CE, Ostile E, Scott CK, et al. A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. Int J Drug Policy. 2020;81:102768. doi:10.1016/j.drugpo.2020.102768.
   PubMed Web of Science ®Google Scholar
• D’Aunno T, Park SE, Pollack HA. Evidence-based treatment for opioid use disorders: a national study of methadone dose levels, 2011-2017. J Subst Abuse Treat. 2019;96:18–22. doi:10.1016/j.jsat.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Bergman BG, Ashford RD, Kelly JF. Attitudes toward opioid use disorder medications: results from a U.S. national study of individuals who resolved a substance use problem. Exp Clin Psychopharmacol. 2020;28(4):449–461. doi:10.1037/pha0000325.
   PubMed Web of Science ®Google Scholar
• Mark TL, Goode SA, McMurtrie M, et al. Improving research on racial disparities in access to medications to treat opioid use disorders. J Addict Med. 2023;17(3):249–257. doi:10.1097/ADM.0000000000001104.
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, et al. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–981. doi:10.1001/jamapsychiatry.2019.0876.
   PubMed Web of Science ®Google Scholar
• Stein BD, Dick AW, Sorbero M, et al. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abuse. 2018;39(4):419–425. doi:10.1080/08897077.2018.1449166.
   PubMed Web of Science ®Google Scholar
• Olfson M, Wall M, Barry CL, et al. Medicaid expansion and low-income adults with substance use disorders. J Behav Health Serv Res. 2021;48(3):477–486. doi:10.1007/s11414-020-09738-w.
   PubMed Web of Science ®Google Scholar
• Kravitz-Wirtz N, Davis CS, Ponicki WR, et al. Association of medicaid expansion with opioid overdose mortality in the United States. JAMA Netw Open. 2020;3(1):e1919066. doi:10.1001/jamanetworkopen.2019.19066.
   PubMed Web of Science ®Google Scholar
• Robles M, Mortazavi L, Vannerson J, et al. How a medication for opioid use disorder curriculum translates into experiences and internal medicine residents’ understanding of patients with opioid use disorder. Teach Learn Med. 2022;34(5):514–521. doi:10.1080/10401334.2021.1897597.
   PubMed Web of Science ®Google Scholar
• Williams JM, Syed MA, Adesanya A, et al. Educating the community about the opioid epidemic and medications for opioid use disorder. Am J Addict. 2022;31(5):433–440. doi:10.1111/ajad.13287.
   PubMed Web of Science ®Google Scholar
• Johnson E, Bolshakova M, Vosooghi A, et al. Effect of didactic training on barriers and biases to treatment of opioid use disorder: meeting the ongoing needs of patients with opioid use disorder in the emergency department during the COVID-19 pandemic. Healthcare (Basel). 2022;10(12):2393. doi:10.3390/healthcare10122393.
   PubMedGoogle Scholar
• Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41(3):275–282. doi:10.1080/08897077.2020.1787299.
   PubMed Web of Science ®Google Scholar
• Kennedy BR, Mathis CC, Woods AK. African Americans and their distrust of the health care system: healthcare for diverse populations. J Cult Divers. 2007;14(2):56–60.
   PubMedGoogle Scholar
• Samples H, Williams AR, Olfson M, et al. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Use Addict Treat. 2018;95:9–17. doi:10.1016/j.jsat.2018.09.001.
   Google Scholar